Lee Kong Chian School of Medicine
Dr. Wang Xiaomeng currently serves as an Assistant Professor at NTU, Principal Investigator at IMCB, Honorary Lecturer at UCL, Research Scientist at SERI. She is an innovative scientist with extensive expertise in the field of vascular biology pertaining to ocular diseases and cancers. Her recent study led to the identification of a novel angiogenic factor, LRG1 and the LRG1 blocking antibody is currently in Phase I clinical trial as a combined treatment strategy with Lucentis® in patients with neovascular AMD. Her work had been published in high impact journals including Nature and Nature protocols. Dr. Wang is also the co-inventor on two international patents relating to LRG1 and its potential as therapeutic target for vasoproliferative conditions and cancers.